The QualityStocks Daily Friday, November 10th, 2023

Today's Top 3 Investment Newsletters

360 Wall Street(MRAI) $0.6845 +80.75%

MarketClub Analysis(DRCT) $4.0400 +54.79%

QualityStocks(MEEC) $0.7330 +48.08%

The QualityStocks Daily Stock List

Midwest Energy Emissions (MEEC)

Wall Street Resources, QualityStocks, Greenbackers, MarketBeat, SeriousTraders, StockEarnings, NBT Equities Research,, PoliticsAndMyPortfolio, MissionIR, TopPennyStockMovers, StockOodles, PennyStocks24 and OTC Markets Group reported earlier on Midwest Energy Emissions (MEEC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Midwest Energy Emissions Corporation (OTCQB: MEEC) is an environmental services and technology firm that is focused on the development and delivery of solutions to the power industry globally.

The firm has its headquarters in Corsicana, Texas and was incorporated in 1983, on July 19th by Richard A. MacPherson. It operates as part of the pollution and treatment controls industry, under the industrials sector. The firm primarily serves clients in Canada and the U.S.

The company specializes in mercury emission control technologies, primarily for utility and industrial coal-fired units. It aims to deliver cost-effective mercury capture technologies to coal-fired power plants in Europe, the U.S. and Asia. Geographically, all the activities function through the United States region and it achieves revenues from equipment sales, product sales and demonstration and consulting services.

The enterprise develops and deploys technologies to remove mercury emissions from coal-fired power plants, helping meet compliance regulations, optimize operations and reduce costs in the area of mercury emissions control. Its portfolio is comprised of its Sorbent Enhancement Additive (SEA) technology, which offers total mercury control, providing solutions that are based on a thorough scientific understanding of actual and probable interactions involved in mercury capture in coal-fired flue gas.

The firm recently entered into a new supply partnership with an existing technology licensee, a move that will bring in significant revenues into the firm while also opening it up to new growth and investment opportunities.

Midwest Energy Emissions (MEEC), closed Friday's trading session at $0.733, up 48.0808%, on 2,774,576 volume. The average volume for the last 3 months is 2.153M and the stock's 52-week low/high is $0.2001/$0.7349.

Tracon Pharmaceuticals (TCON)

MarketBeat, StockMarketWatch, BUYINS.NET, MarketClub Analysis, TradersPro, TraderPower, QualityStocks,, The Stock Psycho, Market Authority, Investing Futures, Market Report, Darth Trader, PoliticsAndMyPortfolio, Wall Street Mover, The Online Investor, The Street, Investors Alley, InsiderTrades and Money Morning reported earlier on Tracon Pharmaceuticals (TCON), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tracon Pharmaceuticals Inc. (NASDAQ: TCON) is a biopharmaceutical firm that is engaged in developing and commercializing therapies for cancer.

The firm has its headquarters in San Diego, California and was incorporated in October 2004. Prior to its name change in March 2005, the firm was known as Lexington Pharmaceuticals Inc. It operates as part of the scientific research and development services industry, under the healthcare sector. The firm has two companies in its corporate family and serves consumers in the United States.

The company is party to license and collaboration agreements with Case Western Reserve University to develop TRC102; I-Mab Biopharma, to develop CD73 antibody TJ004309; Jiangsu Alphamab Biopharmaceuticals Co. Ltd to develop envafolimab; and 3D Medicines Co. Ltd. It is also party to a development agreement with the National Cancer Institute.

The enterprise’s clinical-stage products include a CD73 antibody dubbed TJ004309, which is in phase I clinical development and has been developed to treat solid tumors; a small molecule known as TRC102, which is undergoing phase1 clinical trials for the treatment of glioblastoma, lung cancer, lymphomas and solid tumors and phase 2 clinical trials evaluating its effectiveness in treating mesothelioma. It is also developing YH001 for the treatment of a range of cancer indications and envafolimab, to treat soft tissue sarcoma.

The firm recently announced its latest financial results and remains focused on advancing its product candidates. The success and approval of these formulations will not only benefit patients with certain indications but also bring in additional revenues as well as investors into the firm, which will be good for its growth.

Tracon Pharmaceuticals (TCON), closed Friday's trading session at $0.2303, up 43.9375%, on 75,690,898 volume. The average volume for the last 3 months is 83,006 and the stock's 52-week low/high is $0.1255/$2.19.

Eve Holding (EVEX)

MarketBeat, Wealth Daily, The Stock Dork, Schaeffer's, MarketClub Analysis and InvestorPlace reported earlier on Eve Holding (EVEX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Eve Holding, Inc. (NYSE: EVEX) is an aerospace holding company that, through its subsidiaries, develops Urban Air Mobility Solutions and provides air transportation systems for passenger mobility and goods delivery.

Its headquarters are in Melbourne, Florida and it was formed in 2020 after first emerging as an innovation project at major aircraft manufacturer Embraer. The firm operates in the aerospace and defense industry, under the industrials sector. It has operations in Melbourne city in Florida and Brazil.

The company’s main product line involves developing UAM solutions that include designing and producing electrical vertical takeoff and landing vehicles (eVTOLs). It also provides a suite of maintenance and portfolio services such as material services, maintenance, technical support, training, and ground handling for Eve Holding Inc.’s and third-party eVTOLS as well as fleet operation services together with partner firms. It is also involved in the development of urban air traffic management systems to allow for the safe operation of eVTOLS in urban airspaces alongside drones and aircraft. The firm markets its eVTOL product line globally to UAM service operators such as helicopter and fixed-wing operators and lessors who manage such aircraft on behalf of the operators. Eve Holding Inc. merged with emerging technology investment firm Zanite Acquisition Corp in 2021 and had an IPO on the New York Stock Exchange in 2022, on May 10.

It is committed to leading the evolution of urban mobility and accelerating the world’s transition to sustainable air rides while giving customers unprecedented access to the sky.

Eve Holding (EVEX), closed Friday's trading session at $7.04, off by 2.8966%, on 43,059 volume. The average volume for the last 3 months is 2.376M and the stock's 52-week low/high is $5.10/$11.4899.

Grupo Televisa SAB (TV)

Streetwise Reports, MarketBeat, MarketClub Analysis, Stockhouse, Daily Trade Alert, Schaeffer's, Trades Of The Day, Kiplinger Today,, InvestorPlace, The Street, ProfitableTrading, StreetInsider, Daily Markets, StreetAuthority Daily, StocksEarning, Zacks, DividendStocks, Market Intelligence Center Alert, Louis Navellier, AllPennyStocks, The Online Investor, SmarTrend Newsletters, TopStockAnalysts, TradingMarkets, Top Pros' Top Picks, Penny Stock Buzz, Wealth Daily, InvestorIntel, Investing Signal, FNNO Newsletters, Wyatt Investment Research, Daily Profit, Daily Market Beat and Uncommon Wisdom reported earlier on Grupo Televisa SAB (TV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Grupo Televisa SAB (NYSE: TV) (OTC: GRPFF) (BMV: TLEVISACPO) (FRA: TLV) is a leading media company in Mexico with a focus on producing audiovisual content and providing access to cable and satellite pay television.

The firm is headquartered in Mexico City, Mexico, and was founded in 1973, on January 8, upon the union of Televisión Independiente de México and Telesistema Mexicano. It operates as part of the telecom services industry, under the communication services sector in Spanish-speaking Mexico and international markets.

Grupo Televisa operates in four main segments; Content, Sky, Cable, and Other Businesses. The Content segment encompasses Network Subscription, Advertising, Licensing, and Syndication. The Sky segment provides direct-to-home broadcast satellite pay television services comprising program, installation, and equipment rental services to consumers located in Mexico, Central America, and the Dominican Republic as well as national advertising sales. The Cable segment operates a cable multiple system in the Mexico City metropolitan area that offers basic and premium television subscription, installation, and pay-per-view. This segment also provides internet subscription, mobile, telephone services, local sales and national advertising services, and telecommunication facilities that offer carriers and other telecommunications service providers data and long-distance service solutions via a network of fiber-optic cables. The Other Business segment deals in live entertainment and professional sports, show business and sports promotion, feature film production and distribution, radio production and broadcast, magazine publishing and distribution, and gaming businesses. Grupo Televisa operates broadcast channels in Mexico and around 50 other countries worldwide, serving residential, commercial, enterprise, business, and government customers. The company provides both free-to-air and pay-TV, has interests in the Univision Communications channel, and offers advertising services through its online properties and pay-TV networks.

It is committed to satisfying its customers' entertainment and information needs and meeting its profitability demands while maintaining the highest global standards of quality, creativity, and social responsibility.

Grupo Televisa SAB (TV), closed Friday's trading session at $2.39, off by 0.829876%, on 1,108,138 volume. The average volume for the last 3 months is 2.511M and the stock's 52-week low/high is $2.10/$6.57.

Sunstone Hotel Investors (SHO)

MarketBeat, MarketClub Analysis, StreetInsider,, Daily Trade Alert, Trades Of The Day, The Street Report, Zacks, SmarTrend Newsletters, TheStockAdvisor, Daily Markets, Early Bird, MadPennyStocks, Louis Navellier, Investopedia, HotOTC, FNNO Newsletters, PennyInvest, CoolPennyStocks, BullRally, FreeRealTime, Barchart, Nebula Stocks, PennyStockProphet, PennyStockVille, Short Term Wealth, StockEgg, StockRich, Street Insider, The Street, The Tycoon Report, Trading Markets, WiseAlerts and Momentum Trades reported earlier on Sunstone Hotel Investors (SHO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sunstone Hotel Investors Inc. (NYSE: SHO) (FRA: UF2) is a lodging real estate investment trust (REIT) that currently owns approximately 15 hotels comprising 7,735 rooms.

The company has its headquarters in Aliso Viejo California, United States, and was founded in 2004, on June 28th. It operates in the real estate investment trust industry (hotel & motel), under the real estate sector, and mostly owns properties in the continental USA.

The firm’s portfolio primarily consists of luxury hotels in resort destinations, convention, and urban markets in Florida, California, Hawaii, Massachusetts, Louisiana, Oregon, and Washington, DC. This includes Four Seasons Napa Valley, Boston Park Plaza, Hyatt Regency San Francisco, Oceans Edge Resort & Marina, Marriott Boston Long Wharf, The Bidwell Marriott Poland, JW Marriott New Orleans, Renaissance Orlando at SeaWorld, Hilton New Orleans St. Charles, Wailea Beach Resort, Montage Healdsburg, Hilton San Diego Bayfront, The Westin Washington, DC Downtown, and The Confidante Miami Beach. Sunstone Hotel Investors Inc.’s hotels are operated by third-party managers, typically nationally recognizable brands like Hilton, Hyatt, Marriott, Fairmont, and Starwood, under long-term TRS Lessee agreements. The company’s third-party operators include Marriott International, Inc. which manages six hotels, and Hyatt Hotels Corporation which manages two hotels, as well as Four Seasons Hotels Limited, Sage Hospitality Group, Montage North America, Singh Hospitality LLC, Interstate Hotels & Resorts, Inc, Highgate Hotels L.P. and its affiliate Hilton Worldwide.

It remains committed to creating and maintaining long-term stakeholder value by acquiring, maintaining ownership, and disposing of hotel properties considered to be Long-Term Relevant Real Estate.

Sunstone Hotel Investors (SHO), closed Friday's trading session at $9.65, up 1.9007%, on 2,809,814 volume. The average volume for the last 3 months is 1.345M and the stock's 52-week low/high is $8.6038/$11.375.

Rumble (RUM)

Schaeffer's, MarketBeat, Zacks, Money Wealth Matters, InvestorPlace, Early Bird and 360wallstreet reported earlier on Rumble (RUM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Rumble Inc. (NASDAQ: RUM) is a full-service video technology provider that offers cloud services and web hosting and operates video-sharing platforms in the U.S., Canada, and internationally.

The company’s main headquarters are in Toronto, Ontario, and it was founded in 2013, on October 30. It operates as part of the software application industry, under the technology sector. Rumble, Inc. has offices in Longboat Key, Florida as well.

Its two main business segments are Cloud and Video. The video segment comprises three core products: Rumble, Locals, and Rumble Advertising Center (RAC). The firm operates, a free-to-use online platform that allows web users to subscribe to channels by content creators, access live and video-on-demand (VOD) content, like, comment, share, and stay in touch with their favorite creators. It also operates, an exclusive subscription platform where paying subscribers can engage with content creators through podcasts, community discussions and polls, live chats, and VOD content in an exclusive community. RAC is an advertising marketplace designed to expedite transactions for advertisers interested in marketing on Rumble Inc.’s online platforms. In the Cloud segment, Rumble Inc. is developing Rumble Cloud, a new infrastructure as a service (IaaS) business that is meant to serve the portion of the cloud market disenfranchised by censorship by dominant tech companies. The firm launched a beta release of Rumble Cloud in September 2023 to provide beta customers with a suite of modern cloud services on the latest technologies and hardware. The company’s offerings in this segment include storage services such as object and block storage, cloud computing services, a virtual private cloud, and networking services with load balancers.

It remains committed to protecting a free and open internet by creating technologies that are immune to cancel culture, allow content creators to monetize their content, and grant users access to diverse opinions, ideas, and dialogue.

Rumble (RUM), closed Friday's trading session at $4.69, off by 0.424628%, on 746,719 volume. The average volume for the last 3 months is 1.009M and the stock's 52-week low/high is $4.45/$12.91.

Summit Therapeutics (SMMT)

Schaeffer's, MarketClub Analysis, INO Market Report, TraderPower, Bull in Advantage, TradersPro, StreetInsider, MarketBeat, Zacks, StockMarketWatch, Stockpalooza, QualityStocks, FreeRealTime, BUYINS.NET, Early Bird, BullRally, HotOTC, CoolPennyStocks, InsiderTrades, AllPennyStocks, PennyStockProphet, Stock Rich, The Stock Dork, TooNiceStocks, Trading Concepts and OTCtipReporter reported earlier on Summit Therapeutics (SMMT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Summit Therapeutics Inc. (NASDAQ: SMMT) is a clinical-stage drug discovery and development biopharmaceutical firm that focuses on discovering, developing, and commercializing novel antibiotics for serious infectious diseases.

Its headquarters are in Menlo Park, California and it was incorporated in 2020, on July 17. The company operates in the biotechnology industry, under the healthcare sector, and primarily develops oncology solutions in the U.S. and the UK. It has additional offices in Oxford, UK.

The firm is primarily involved in researching and developing oncology-related and anti-infective products. Its line of products includes a novel class of antibiotics called SMT-738 that is currently in preclinical research stages for the treatment of multi-drug resistant infections such as carbapenem-resistant Enterobacteriaceae (CRE) infections and c. difficile infection. The lead candidate in this antibiotic class is ridinilazole, an oral small-molecule antibiotic, and investigational therapy currently being studied in the treatment of c. difficile infection. Summit Therapeutic’s December 2017 acquisition of Discuva Ltd. granted it access to the proprietary genetics-based Discuva Platform and a suite of software-based technologies that aid the firm in its core tenets of identifying novel targets, elucidating mechanisms of action, and optimizing treatments against bacterial resistance. The company has a collaboration and license agreement with biopharmaceutical company Akeso Inc. to research and develop novel, potential first-in-class bispecific antibody Ivonescimab and SMT112, a promising anti-tumor therapy candidate.

It remains committed to developing innovative, patient-friendly medicinal therapies designed to meet serious unmet medical needs, increase potential duration of life, and improve quality of life in a rapid and cost-efficient manner.

Summit Therapeutics (SMMT), closed Friday's trading session at $1.905, up 8.547%, on 824,038 volume. The average volume for the last 3 months is 67,089 and the stock's 52-week low/high is $0.66/$5.78.

Bit Mining Ltd. (BTCM)

QualityStocks, MarketClub Analysis, StockEarnings, Schaeffer's, CryptoCurrencyWire, Wall St. Warrior, The Stock Dork, StocksEarning, smartmoneytrading, MarketBeat, INO Market Report and 247 Market News reported earlier on Bit Mining Ltd. (BTCM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The recent conclusion of Sam Bankman-Fried’s trial has sparked contemplation on the future trajectory of the cryptocurrency industry. The verdict, which found Bankman-Fried, the founder of cryptocurrency exchange FTX, guilty of seven counts of fraud, has left many questioning the implications for the crypto market.

Amid this significant development, the core inquiry emerges: What impact will this verdict have on the reputation and prospects of the burgeoning crypto space? Will it etch a lasting blemish on the industry, leading to skepticism and mistrust, or could it signal a moment of closure, showcasing the capacity of legal systems to hold wrongdoers accountable, thereby solidifying confidence in the market’s integrity?

Various perspectives from notable figures within the cryptocurrency sphere shed light on this momentous outcome.

Paul Brody, EY’s head of blockchain, lauded the verdict, emphasizing the importance of accountability in the crypto sector. He stated, “This is a very exciting time for cryptocurrencies. Accountability and the belief that wrongdoers will face consequences are crucial, not just to discourage wrongdoers but also to inspire trust in those who are acting with integrity.”

Noelle Acheson, a former head of research at CoinDesk, expressed relief at the verdict, asserting that it will contribute to portraying crypto markets as mature and accountable, vital for attracting a new wave of investors. Crypto Council for Innovation CEO Sheila Warren highlighted the trial’s focus on fraud and underscored the importance of directing attention toward the victims and steering away from glorifying wrongdoers.

Senator Sherrod Brown, who chairs the Banking, Urban, and Housing Affairs Senate Committee, emphasized the significance of the verdict in combating fraudulent practices within the crypto sphere, advocating for a crackdown on abuses and emphasizing the need for regulatory oversight.

Legal experts such as Preston Byrne and Joshua Klayman interpreted the trial’s outcome as a pivotal victory in demonstrating that even within the complexities of cryptocurrency, fraudulent activities can be prosecuted. Klayman indicated that this could embolden prosecutors to pursue similar cases, underscoring the importance of accountability to foster a safer environment for the digital asset market.

Michael Selig, counsel in the Asset Management Department, highlighted the trial as a step toward resolution, allowing for a potential reset in the crypto industry’s relationship with regulators and lawmakers.

In considering the aftermath of the verdict, Kevin J. O’Brien, a former assistant U.S. attorney, opined that an appeal appears unlikely. He suggested a probable sentence in the range of 15 to 20 years for Bankman-Fried, highlighting the importance of not solely focusing on penalization but allowing for the possibility of future rehabilitation.

Yat Siu, executive chairman at Animoca Brands, remarked on the trial’s impact, asserting that it signifies a new beginning for the industry and emphasizing that it was a case of fraud rather than an inherent issue within the cryptocurrency space. Siu highlighted the importance of consequences for wrongdoers, emphasizing the increased sense of security this verdict might bring to market participants.

The collective sentiment echoes the significance of this trial in redefining the industry’s stance on fraudulent practices.While it serves as a reminder of the potential legal repercussions for fraudulent activities, it also presents an opportunity for the industry and its leading actors such as Bit Mining Ltd. (NYSE: BTCM) to pivot towards a future characterized by greater accountability, integrity, and a focus on technological innovation.

Bit Mining Ltd. (BTCM), closed Friday's trading session at $2.77, off by 4.1522%, on 131,771 volume. The average volume for the last 3 months is 2.497M and the stock's 52-week low/high is $1.40/$5.49.

Cronos Group Inc. (CRON)

InvestorPlace, Schaeffer's, Kiplinger Today, MarketClub Analysis, The Street, MarketBeat, StocksEarning, Daily Trade Alert, Trades Of The Day, Wealth Insider Alert, The Online Investor, Market Intelligence Center Alert, QualityStocks, StockMarketWatch, StreetInsider, BUYINS.NET, StockEarnings, Zacks, The Wealth Report, Top Pros' Top Picks, Stock Up Featured, Investopedia, Cabot Wealth, Daily Profit, InvestmentHouse, Early Bird, InsiderTrades, Jim Cramer, The Rich Investor, InvestorsObserver Team, VectorVest, Money Morning, TheTradingReport, Wall Street Window, 24/7 Trader, Small Cap Firm, Stock Gumshoe and InvestorsUnderground reported earlier on Cronos Group Inc. (CRON), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recent study investigating the impact of CBD availability on opioid prescriptions has revealed that although legalizing CBD alone does not automatically reduce the rate of opioid prescriptions, making legal CBD products readily available and affordable has significantly reduced the number of opioid prescriptions by approximately 8.1%.

The study, which was recently published in the “Journal of Southern Economics,” suggests that three key factors impact the opioid crisis: prescription CBD legalization, regulations that limit CBD purchases and access through CBD dispensaries.

To conduct the study, the authors scrutinized state laws concerning restricted-access, CBD-only regulations in states such as Texas, Iowa and Tennessee from 2010 to 2019, which allowed the prescription of CBD products to patients with specific medical conditions. The study acknowledges that during this period, the CBD market was expanding rapidly, with over-the-counter (OTC) use growing at the fastest rate. However, in the early stages of the study, OTC CBD products were not generally accessible because the majority of states had not yet created industrial hemp programs until 2016.

While the presence of CBD dispensaries appeared to have a meaningful impact on reducing opioid prescriptions, this benefit was nullified when strict rules governing CBD access were in place. Additional regulations, such as ID requirements and patient registries, almost entirely negated the positive effects of CBD dispensaries on opioid reduction.

The study indicates that legalizing CBD alone decreased the number of opioid prescriptions, although not as significantly as comprehensive recreational and medical laws. States that had legalized marijuana for both medical and recreational purposes tended to prescribe fewer opioids per 100 residents than states that did not. However, these regions also tended to have healthier populations and higher concentrations of medical professionals, indicating that the variations in opioid use could not be exclusively related to the legalization of cannabis.

Prescription rates for opioids generally decreased during the research period, most likely as a result of the rise in overdose deaths involving opioids. Between 2010 and 2018, states with medical cannabis laws saw a 35% decline in the number of opioid prescriptions, while states without any kind of cannabis legalization saw a 33% decrease.

The findings of the study indicate that the imposition of ID checks or patient registries for CBD purchases did not significantly affect the rates of opioid prescriptions, even in states where CBD dispensaries are present. This, according to the study, underscores the notion that regulatory barriers may impede the potential advantages of legalizing CBD for tackling the opioid problem.

The study concludes by highlighting the need for legislators to carefully weigh the trade-offs between limiting access and regulating CBD for quality since strong regulations impede CBD’s significant influence on the rates of opioid prescriptions.

The evolving laws around CBD and marijuana permitting enterprises such as Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) to bring innovative products onto the market could help patients find alternatives to opioids and thereby put the brakes on the escalating opioid crisis.

Cronos Group Inc. (CRON), closed Friday's trading session at $2.06, up 4.5685%, on 2,038,037 volume. The average volume for the last 3 months is 5.254M and the stock's 52-week low/high is $1.64/$3.616.

VinFast Auto Ltd. (VFS)

Schaeffer's, MarketBeat, Early Bird, QualityStocks and InvestorPlace reported earlier on VinFast Auto Ltd. (VFS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Like many other developed nations around the globe, the United States plans to decarbonize its economy as part of efforts to mitigate global warming and stop climate change. This will require mass adoption of electric vehicles, alternative energy cars that use rechargeable batteries rather than fossil fuel to run.

Electric cars still make up a relatively small percentage of total vehicle sales in the U.S., but Americans are adopting EVs in steadily increasing numbers. According to a recent study published in “Joule,” it seems that America’s growing number of EV owners may be driving fewer miles per year compared to fossil fuel vehicle drivers.

Before this research, regulatory bodies such as the Environmental Protection Agency (EPA) assumed that EV owners and gas vehicle owners traveled similar distances each year. However, the research presents evidence that counters this assumption and raises the question of whether we have been overestimating electric vehicle emissions savings.

Researchers from the National Renewable Energy Laboratory and the George Washington University recently carried out one of the largest EV mileage studies so far, examining odometer data collected from 2016 to 2022 from 11.9 million used SUVs and 12.9 million used cars.

The researchers discovered that battery electric vehicles traveled nearly 4,500 miles less per year compared to diesel and petrol-powered cars. Fossil fuel SUVs traveled 12,945 miles while electric SUV owners drove their EVs only 10,587 miles annually in comparison. Additionally, passenger fossil fuel cars traveled 11,642 miles and electric passenger cars traveled 7,165 miles.

John Helveston, study coauthor and a George Washington University assistant professor of engineering management and systems engineering, said that while many people are under the assumption that switching to electric vehicles is good for the ecosystem, the impact of EVs on carbon emissions scales with their mileage.

Helveston said the research team’s findings indicated that current electric vehicle owners aren’t using the vehicles as much as fossil fuel car drivers are using theirs, potentially reducing the positive environmental impact of electric cars. To maximize the environmental benefits of electric cars, Helveston said that the nation’s highest-mileage drivers, rather than low-mileage drivers, should own and operate EVs.

The research team also discovered that Teslas are driven more compared to other electric vehicle brands, likely because Tesla models often have higher ranges and can access a wide network of fast-charging stations. Plug-in hybrid and hybrid drivers also traveled a relatively similar amount of miles as fossil fuel car drivers.

For manufacturers that are looking to make inroads into the American market, such as VinFast Auto Ltd. (NASDAQ: VFS), strategies must be found to ensure their models can access charging facilities in more places across the country so that the increased use of these vehicles can encourage more people to buy EVs.

VinFast Auto Ltd. (VFS), closed Friday's trading session at $6.07, off by 6.4715%, on 3,544,314 volume. The average volume for the last 3 months is 5.182M and the stock's 52-week low/high is $4.59/$93.00.

Seelos Therapeutics Inc. (SEEL)

QualityStocks, MarketBeat, StockEarnings, StockMarketWatch, MarketClub Analysis, TradersPro, Schaeffer's, BUYINS.NET, Trades Of The Day and INO Market Report reported earlier on Seelos Therapeutics Inc. (SEEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A psychedelic task force commissioned to research the therapeutic benefits of LSD, MDMA and psilocybin in Minnesota and prepare the state for possible psychedelic legalization recently held its first meeting. Task force members chose a chairperson during the meeting and outlined a plan for the next few months.

The psychedelic task force was formed in late May when the Minnesota legislature passed a large-scale health policy bill with psychedelic-centered language and sent it to Governor Tim Walz’s desk. The legislation established a Psychedelic Medicine Task Force and charged it with advising legislators on the medical, policy and legal issues associated with legalizing therapeutic psychedelic use in Minnesota.

The 25-member task force held its first meeting more than three months late, but State Representative Andy Smith, the sponsor of a standalone psychedelic task force measure, believes the task force will “hit the ground running.”

According to the task force, 24 of the 25 posted task force positions have already been filled with agency representatives, lawmakers and experts in mental health, psychedelic medicine, substance-use disorders, health policy and veteran health. The state omnibus legislation that created the task force required that it consist of experts and officials including the health commissioner, a governor or designee, two tribal representatives, the state attorney general or a designee, and experts in various mental health and public health-related issues.

The task force was required to issue two reports to health and human services legislative committees with comprehensive coverage of psychedelic legalization in Minnesota by Feb. 1, 2024, and Jan. 1, 2025.

Task force members elected the Psychedelic Society of Minnesota executive director and University of Minnesota Medical School assistant professor Jessica Nielsen as task force chairperson.

Smith said the Department of Health team has done a lot of groundwork to get ready for fieldwork. The representative noted the team had already started training task force members on the presentation software and technology they would use in their activities. He said that he was excited to see the task force convening and was especially encouraged by the fact that psychedelic legalization in Minnesota seemed to draw bipartisan support.

According to Smith, the relatively new field of psychedelic medicine has the potential to help thousands and even millions of Minnesota residents who are currently grappling with all kinds of mental health issues.

Recent advances in psychedelic research have found that hallucinogenic drugs such as LSD, psilocybin, ayahuasca and MDMA can offer long-term relief against various mental ailments with barely any side effects and at relatively small doses, especially when paired with psychotherapy.

Task force member Representative Nolan West noted that traditional mental-health treatments often have side effects and said he was excited to see trained health professionals offer informed opinions and aid the task force in its quest to help Minnesotans.

The psychedelic board is likely to follow closely the research findings of companies such as Seelos Therapeutics Inc. (NASDAQ: SEEL) that are focused on developing psychedelics-based treatments to address the clinical needs of people with mental health disorders.

Seelos Therapeutics Inc. (SEEL), closed Friday's trading session at $0.1451, off by 10.2104%, on 5,390,462 volume. The average volume for the last 3 months is 817,134 and the stock's 52-week low/high is $0.14/$1.66.

Curaleaf Holdings Inc. (CURLF)

InvestorPlace, Kiplinger Today, MarketBeat, QualityStocks, Cabot Wealth, Daily Trade Alert, Top Pros' Top Picks, MarketClub Analysis, Profit Trends, The Online Investor, StreetInsider, Wealth Insider Alert, Early Bird, Trades Of The Day, Trading For Keeps, The Street, Investment U, Daily Profit, CFN Media Group, StreetAuthority Daily, Zacks, TradersPro, Wyatt Investment Research, wyatt research newsletter and Schaeffer's reported earlier on Curaleaf Holdings Inc. (CURLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Home values in states with legal cannabis markets have grown at significantly faster rates over the past decade compared to prohibitionist states. According to a Leafly and Real Estate Witch study, homes in cannabis states are 41% higher in value than homes in states without legal cannabis markets.

The paper looked at the potential impact of recreational or medical cannabis markets on average American home prices from 2014–2023.

Although states such as California began legalizing medical cannabis more than a decade ago, the past decade has seen a multitude of states legalize the controversial plant. With dozens of states now allowing medical and recreational cannabis, tens of millions of Americans now have access to either medical or adult-use marijuana.

However, several states still outlaw both recreational and medical cannabis, meaning there are plenty of Americans who are still criminalized for cannabis possession and use.

Cannabis remains the most used drug in the country, even in states that still criminalize it, and it seems the drug may now be affecting real estate values across the country. The analysis revealed that average home prices in states with recreational cannabis markets increased by $185,075 since 2014 compared to $136,092 in states without adult-use markets.

As a result, average home prices in recreational cannabis states hit $417,625 by the end of the study period while average home prices in nonrecreational marijuana states were 41% lower at $295,338. States with medical marijuana markets also registered faster home value growth compared to states without medical cannabis reform, growing by an average of $166,609 since 2014 compared to $137,320 in prohibitionist states.

According to the report, it isn’t surprising that states that embraced cannabis reform are registering significant increases in home values because real estate always appreciates over time. However, the gap between states with cannabis markets and prohibitionist states “sticks out like a green thumb,” the report noted.

There was even evidence of cannabis reform affecting home values at local levels with cities that had licensed cannabis retailers seeing an average home price increase of $168,292 since 2014. In comparison, cities without cannabis dispensaries saw an increase of only $100,933 in the same period, indicating that cannabis legalization may have some effect on property values.

Leafly vice president of brand and communication Josh deBerge said the report is evidence of what many cannabis community insiders have known for a long time: cannabis reform does not diminish property values. Rather, licensing cannabis firms such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) boosts demand for residential and commercial property.

Curaleaf Holdings Inc. (CURLF), closed Friday's trading session at $3.28, up 7.8947%, on 333,216 volume. The average volume for the last 3 months is 261,853 and the stock's 52-week low/high is $2.19/$7.90.

The QualityStocks Company Corner

Renovaro BioSciences Inc. (NASDAQ: RENB)

The QualityStocks Daily Newsletter would like to spotlight Renovaro BioSciences Inc. (NASDAQ: RENB) .

The agreement with GEDiCube rebrands the company as a wholly-owned subsidiary under the name Renovaro.AI

The combined company brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early detection, diagnostic insights, and targeted immunotherapies, for cancer and other diseases

The AI division intends to launch commercial products for early cancer detection and improved therapy selection in 2024 – rapidly expanding the largely untapped precision medicine market

In September, Renovaro Biosciences (NASDAQ: RENB), an advanced, preclinical biotechnology company focused on cell, gene, and immunotherapy, and GEDiCube Intl Ltd., an AI medical technology company, announced a definitive agreement for combination. Under the stock-for-stock agreement, GEDiCube will become a wholly-owned subsidiary of Renovaro. The company's CEO, Dr. Mark Dybul, MD, recently sent a letter to Renovaro shareholders to provide an update on the union – sharing the vision of the combination and expressing appreciation for their ongoing support and investment (

Renovaro BioSciences Inc. (NASDAQ: RENB), formerly Enochian BioSciences Inc., is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, and to potentially treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) infection.

The oncology platform is now at the forefront of Renovaro’s development activities. While Renovaro’s current efforts focus primarily on pancreatic cancer, it plans to include other solid tumors with short life-expectancy in the first in human Phase I/IIa studies that are on track to start by mid-2024. The company’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat, potentially including triple-negative breast cancer, head and neck cancers and mesothelioma.

Renovaro’s proprietary, novel technology uses cell- and gene-therapy to promote a renewed immune response against solid tumors. Important confirmatory results from two humanized mouse models using the company’s novel dendritic cell-based therapy, independently conducted by Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy at UCLA, were presented previously at two scientific conferences and were the foundation supporting a pre-IND submission to the U.S. Food and Drug Administration. Notably, Dr. Jewett’s findings from these studies consistently demonstrated 80% to 90% pancreatic tumor reduction in size and weight that was correlated with significant enhancement of key aspects of the immune response.

Renovaro is headquartered in Los Angeles, California.


Renovaro’s product development strategy is anchored in the use of “non-self” or allogeneic cells that enhance targeted immune response. Its lead candidate, RENB-DC11, is an innovative therapeutic vaccination platform that could potentially be used to induce life-long remissions from some of the deadliest solid tumors.
Treatment with RENB-DC11 has now been shown to significantly reduce the size of human pancreatic tumors in humanized mice in three independent studies. The reduction in tumor size correlated with statistically significant increases in key components of an immune response.

Pre-IND was completed in June 2023, with IND filing forecast for first half of 2024. First in-human Phase I/IIa trials are predicted shortly after in H1 of 2024, including pancreatic and other solid tumors with poor treatment options and life-expectancy.

Renovaro believes that RENB-DC11 could represent the most promising and effective strategy to achieve life-long remission for a number of common and deadly tumors.

Other Development Candidates

In addition to its lead oncology platform, Renovaro’s development pipeline includes a platform targeting infectious diseases, including:

  • RENB-HV12 – An engineered allogeneic T-Cell vaccine, this therapeutic HIV vaccine candidate enhances immune infiltration, immune killing and immune surveillance. Potential pre-IND submission is planned for first half of 2024, with IND-submission expected in second half of 2024.
  • RENB-HV21 – Leveraging allogeneic NK plus Gamma Delta T (GDT) cells as potential therapy for HIV, ENOB-HV21 shows promising preliminary results without confounding factors. Renovaro owns an exclusive license and has completed the Pre-IND submission, with a potential IND submission and human trials expected in 2024.
  • RENB-HV01 – Caring Cross, a non-profit corporation, has shown that its proprietary CAR-T cells cure HIV in a mouse model. Studies in humans have begun. Renovaro has entered into a profit-sharing sublicense with Caring Cross and would share in profits if the product is commercialized.
  • RENB-HB01 – This therapeutic approach aims to eliminate all HBV rapidly (“seek and kill”) with a two to three dose treatment regimen. It is expected to be applicable for early disease to maximize impact with low risk of toxicity. Pre-IND comments have been received from the FDA for its AAV-delivery system.
    LOI to Merge with GEDi Cube International Ltd.

On August 9, 2023, Renovaro announced its execution of a binding, exclusive letter of intent to merge a subsidiary with cutting-edge health AI company GEDi Cube International Ltd. The combined company is expected to create a potential multiplier effect to accelerate earlier diagnosis, more effective therapy, and precision in silico drug discovery.

GEDi Cube’s innovative technology, developed over nearly a decade, has already validated earlier diagnoses of lung cancer in humans at a leading university hospital. GEDi Cube has likewise created the early diagnosis technology for 12 additional cancers, including pancreatic and breast cancer.

“I believe joining forces with GEDi Cube could enhance the efficacy of our upcoming trials and speed up the discovery of novel treatment approaches, thereby extending our life-saving technology to more cancer patients and renewing hope for them and their families,” Dr. Mark Dybul, CEO of Renovaro, stated in the news release.

GEDi Cube is led by CEO Craig Rhodes, who brings to that company tremendous industry experience leading life sciences groups at industry leaders Intel, Oracle and NVIDIA.

Market Opportunity

Pancreatic cancer alone is diagnosed globally in approximately 495,000 people each year, including roughly 64,000 in the U.S. Nearly 466,000 of those patients die annually, including approximately 51,000 in the U.S. Because of limited treatment options, life expectancy is very poor – with an approximately 10% patient survival rate at five years after diagnosis.

The global pancreatic cancer treatment market was valued at $2.15 billion in 2021 and is projected to grow from $2.48 billion in 2022 to $6.85 billion by 2029, according to Fortune Business Insights. That growth represents a CAGR of 15.7% for the forecast period.

A separate report from Fortune Business Insights projects that the global HIV drug market will grow from $30.46 billion in 2021 to $45.58 billion in 2028, recording a CAGR of 5.9% over the forecast period.

According to GlobalData, the value of the market for hepatitis B treatment is forecast to experience a significant increase in the coming years, with revenues expected to grow from $1.6 billion in 2022 to $10.5 billion in 2029. That represents a very rapid CAGR of 30% over the period. An estimated 296 million people suffer from the condition worldwide.

Management Team

Dr. Mark Dybul is the CEO of Renovaro. He has served as a tenured professor in the Department of Medicine at Georgetown University Medical Center since June 2017. He also served as Faculty Co-Director of the Center for Global Health and Quality from 2017-2021. Dr. Dybul has worked on HIV and public health for nearly 30 years as a clinician, scientist, teacher and administrator, including as an architect and eventually the Global Ambassador of the U.S. President’s Emergency Plan for AIDS Relief and the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2013 through May of 2017, and as the co-director of the Global Health Law Program at the O’Neill Institute for National and Global Health Law from 2009 through 2012. He is a member of the U.S. National Academy of Medicine.

Luisa Puche is the company’s CFO. She has served as a senior accounting and financial advisor and president of Puche Group LLC from 2015-2019. She served in various key executive roles, including Interim Chief Accounting Officer, at Brightstar Corp., a $10 billion global wireless device services provider. Ms. Puche began her career at Ernst & Young, where she served for approximately 10 years. Leveraging her broad global audit, advisory and corporate expertise, she has provided strong cross-functional leadership experience managing small and large projects for both publicly traded and privately held companies in various industries, including a global implementation of the latest revenue recognition accounting standard for Del Monte, as well as the global implementation of their SOX-404 program.

Francois Binette, Ph.D., is the Chief Operating Officer and Executive Vice President of Research & Development at Renovaro. He has over 25 years of product development expertise in Advanced Therapies and Regenerative Medicine. His broad industry experience spans a wide range of serious medical conditions, from orthopedics to ophthalmology, CNS and immuno-oncology. His career includes positions at Genzyme, Biosyntech, the DePuy Franchise of Johnson and Johnson, Medtronic and Lineage Cell Therapeutics. He received his Ph.D. from Laval University in Québec, followed by post-doctoral training at the Sanford-Burnham Institute in La Jolla and Harvard Medical School in Boston.

Renovaro BioSciences Inc. (NASDAQ: RENB), closed Friday's trading session at $2.94, up 5.3763%, on 57,864 volume. The average volume for the last 3 months is 12,339 and the stock's 52-week low/high is $0.3928/$5.25.

Recent News


The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

The United Postal Service (UPS) recently announced that it will spend more than $1 billion this quarter on the acquisition of two companies to increase its reach in e-commerce and bolster its revenue. Currently the largest parcel delivery firm on the globe, UPS has been grappling with increasing competition from rival delivery companies such as FedEx, DHL, DB Schenker and the federal agency United States Postal Service. In late October, UPS cut its revenue projections for the year citing lower demand in the e-commerce sector. The impending $1 billion acquisitions are most likely an attempt by UPS to boost its e-commerce sales volumes and increase profits. Last week, UPS said it had signed an agreement to purchase Happy Returns, a platform that offers box-free returns to hundreds of merchant customers, from PayPal. A month before that, the parcel delivery giant signaled that it intended to buy MNX Global Logistics, a healthcare specialist that offers global logistics and shipping services. The foray of UPS into healthcare e-commerce suggests that healthcare e-commerce companies such as NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW) could see the entities they work with making use of the expanded service offerings of UPS to this segment.

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

  • E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
  • Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
  • NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
  • Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Friday's trading session at $1.86, up 4.7887%, on 20,776 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $5.25/$.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene, a company targeting the treatment of neurodegenerative diseases that severely impact people's lives, is currently focusing on amyotrophic lateral sclerosis ("ALS") alongside other neurodegenerative diseases

The company's wholly owned subsidiary, Clene Nanomedicine, and two collaborators, Columbia University and Synapticure, are the recipients of a four-year grant totaling $45.1 million

The grant will support an Expanded Access Protocol ("EAP") study for Clene's investigational product, CNM-Au8(R)

CNM-Au8 is an orally administered gold nanocrystal suspension that is thought to improve mitochondrial health and protect neuronal function to treat neurodegenerative diseases, including ALS

The EAP study will give patients who did not initially meet the criteria to enroll in a clinical trial an opportunity to try CNM-Au8, which, besides being well tolerated, has improved the survival of ALS patients

In late December of 2021, President Biden signed into law H.R. 3537, the Accelerated Access to Critical Therapies for ALS Act ("Act for ALS") ( The Act for ALS (amyotrophic lateral sclerosis), now public law, directs the Department of Health and Human Services through the Secretary to, among others, "award grants to participating entities for the purposes of scientific research utilizing data from expanded access to investigational drugs for individuals who are not otherwise eligible for clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS" ( During the financial year 2023, the National Institutes of Health ("NIH") made strides to implement the Act for ALS, extending its commitment to advancing research on ALS, which currently has no cure. Through its division, the National Institute of Neurological Disorders and Stroke ("NINDS"), the NIH issued three new awards for the grant program prescribed in the Act for ALS ( One of these awards, a four-year grant totaling $45.1 million, went to Clene Nanomedicine Inc., a wholly owned subsidiary of Clene (NASDAQ: CLNN), and its collaborators, Columbia University and Synapticure.

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.


CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Friday's trading session at $0.45, up 12.2195%, on 506,920 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3576/$1.99.

Recent News

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0)

The QualityStocks Daily Newsletter would like to spotlight Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0).

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FSE: GDT0) is a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure and private communications. "Sekur Private Data distributes a communications suite that offers encrypted and private email, the only Swiss-hosted privacy VPN, and a secure and private messaging application, catering to consumers, SMBs, enterprises, and governments. Unlike other competitors in the industry, Sekur owns 100% of its own infrastructure without relying on third-party cloud services like Amazon Web Services, Microsoft Azure Cloud or Google Cloud infrastructure," a recent article reads. "With all the threats, including dual ransomware attacks, Sekur offers customers a confidential and safe way to store their information in Switzerland using military-grade security. All data, whether physical, network-based or encryption security, is stored in bank-approved, state-of-the-art ISO-certified data centers used by Swiss and global banks and most UN organizations, corporations and governmental organizations – the location is chosen because of the country's neutrality, independence, strong privacy laws, long-standing political stability, and excellent international relations."

To view the full article, visit

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0) is a Cybersecurity and Internet privacy provider of Swiss hosted solutions for secure and private communications. The company distributes a suite of encrypted e-mails, secure messengers and secure communication tools. Sekur Private Data Ltd. sells its products through its own website at, approved distributors, and telecommunications companies. Sekur Private Data Ltd. serves consumers, businesses and governments worldwide.

Customer information is completely confidential and safely stored in Switzerland using military grade security. All data, whether physical, network-based or encryption security, is stored in bank-approved, state-of-the-art ISO-certified data centers used by Swiss and global banks and most United Nations organizations, as well as many corporations and governmental organizations. All user data is protected by the Swiss Federal Data Protection Act and the Swiss Federal Data Protection Ordinance, which offer some of the strongest privacy protection in the world for both individuals and organizations.

The company owns 100% of its own infrastructure and, unlike its competitors, does not rely on third party cloud services like Amazon Web Services, Microsoft Azure Cloud or Google cloud infrastructure.

Sekur Private Data has chosen Switzerland to locate its data storage because of the country’s neutrality, independence, strong privacy laws, long standing political stability and excellent international relations. Switzerland is also home to several large multinational corporations and is ranked as having one of the strongest and most competitive economies in the world.

The company is headquartered in Toronto, Ontario.


Sekur Private Data distributes a privacy communications suite offering encrypted and private email, the only Swiss-hosted privacy VPN, and a secure and private messaging application. All solutions cater to consumers, SMBs, enterprises and governments.

  • SekurMail® is an encrypted email service offering a private, safe and powerful tool to communicate with everyone, either within the Sekur ecosystem or outside. SekurMail protects personal information and communications from being accessed by unauthorized parties. Its encryption and other security measures prevent messages from being intercepted, modified or tampered with, either in transit or while stored. SekurMail empowers the client to access information and communicate with anyone in the world, regardless of geographical or political barriers.
  • SekurVPN® creates a secure, encrypted connection between the client’s device and the Internet, giving clients access to the web safely and privately by routing their connections through a server and hiding their online actions. All the data sent and received is hidden from prying eyes. This includes the clients’ Internet Service Providers, as well as potential hackers and even government surveillance agencies. It can also help clients bypass geographical restrictions and censorship.
  • SekurMessenger® is a Swiss-hosted private and secure messaging communications app providing secure and private chat, self-deleting chat, voice recording and file transfer via any mobile device, tablet or desktop computer. Communications are transmitted only within secure servers. It’s designed for organizations that need to protect their flow of information and secure their communications with customers and partners. SekurMessenger is designed to provide military-grade encryption and privacy by ensuring that only the sender and intended recipient can read the messages exchanged. It works for both licensed users of the app and intended message recipients who do not have the app.

Market Opportunity

An analysis from ReportLinker forecasts that the global cybersecurity market will grow from an estimated $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors that are driving cybersecurity market growth, according to the report.

The global data privacy software market was estimated to be worth $1.68 billion in 2021 and is expected to grow from $2.36 billion in 2022 to $25.85 billion by 2029, achieving an eye-popping 40.8% CAGR during the forecast period, according to a Fortune Business Insights report titled ‘Data Privacy Software Market 2022-2029’.

The widespread shift toward remote working culture, evolving government data privacy regulations and the rapidly increasing adoption of Internet-of-Things devices are among the major factors propelling market growth, per the report.

Management Team

Alain Ghiai is founder, CEO and Director at Sekur Private Data. He also founded GlobeX Data S.A. (GDSA) in 2007 and has served as Director and CEO since then. He founded GlobeX Data Inc. (GlobeX US) in August 2012 and has served as Director and CEO since that time. He attended the California College of Arts in San Francisco, where he earned a Bachelor of Architecture. He has over 15 years of experience in the software industry and was instrumental in taking Sekur Private Data public in July 2019.

Scott Davis, CPA, CGA, is CFO at Sekur Private Data. He is also a partner at Cross Davis & Company LLP Chartered Professional Accountants. His experience includes CFO positions at several companies listed on the TSX Venture Exchange. He spent four years at Appleby as an Assistant Financial Controller. Prior to that, he spent two years at Davison & Company Chartered Professional Accountants as Auditor, five years with Pacific Opportunity Capital as Accounting Manager and two years at Jacobson Soda and Hosak, Chartered Professional Accountants. He obtained his CPA, CGA in 2003.

Learn more about the company’s management team by visiting its corporate page.

Sekur Private Data Ltd. (OTCQB: SWISF), closed Friday's trading session at $0.07, up 7.6923%, on 51,300 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.027/$0.1576.

Recent News

Mountain Top Properties Inc. (OTC: MTPP)

The QualityStocks Daily Newsletter would like to spotlight Mountain Top Properties Inc. (OTC: MTPP).

Mountain Top Properties (OTC: MTPP) specializes in property management, property technology ("PropTech") and real estate redevelopment. "The company's flagship subsidiary is Mountain Top Realty Inc., the managing partner of its first real estate fund focused on residential redevelopment in the prestigious and storied Hamptons, New York, beachfront communities. Mountain Top Properties is also the lead investor in blockchain-enabled industrial and warehouse flex space HQXpress, which services the warehousing, reverse logistics and liquidation markets. The company is in negotiations for the addition of AI-powered technologies that promise to simplify real estate services, including purchasing and sales," a recent article reads. "Mountain Top Capital Fund I LLC is a New York limited liability company recently organized by affiliates of Mountain Top Realty, manager of the fund. Through this fund, Mountain Top Realty will leverage the company's experience, market conditions and industry relationships to capitalize on real estate projects as they arise. This partnership will be focused on waterfront or water view properties in the Hamptons. The Hamptons market has historically remained strong and continues to set new highs year over year."

To view the full article, visit

Mountain Top Properties Inc. (OTC: MTPP) is a diversified real estate holding company that acquires, sells and operates assets through its wholly owned subsidiaries and limited partnerships. The company specializes in property management, property technology (“PropTech”) and real estate redevelopment.

Mountain Top Properties was incorporated in 1990 and is based in Liverpool, New York, with offices in Sag Harbor, New York.


The company’s flagship subsidiary is Mountain Top Realty Inc., the managing partner of its first real estate fund focused on residential redevelopment in the prestigious and storied Hamptons, New York, beachfront communities.

Mountain Top Properties is also the lead investor in blockchain-enabled industrial and warehouse flex space HQXpress, which services the warehousing, reverse logistics and liquidation markets.

The company is in negotiations for the addition of AI-powered technologies that promise to simplify real estate services, including purchasing and sales.

Mountain Top Capital Fund I LLC

Mountain Top Capital Fund I LLC is a New York limited liability company recently organized by affiliates of Mountain Top Realty, manager of the fund. Through this fund, Mountain Top Realty will leverage the company’s experience, market conditions and industry relationships to capitalize on real estate projects as they arise.

This partnership will be focused on waterfront or water view properties in the Hamptons. The Hamptons market has historically remained strong and continues to set new highs year over year.

The fund has partnered with On Site Builder Construction Co. Inc., which is managed by Joseph Kelley, who, for over 40 years, has continued to build the highest quality architecturally designed custom houses, varying in style from classic to ultra-modern, in the Hamptons. Several houses he has built are showcased in books and magazines and featured across various forms of digital and social media. His assembled team of skilled subcontractors are among the finest skilled craftsmen in their various fields of expertise.

Mr. Kelley has built over 60 custom homes in this market and has the unique distinction of building the most expensive house sold in Sag Harbor in 2014, which sold for $31,750,000; the most expensive house in the Hamptons in 2019, which first sold for $27,500,000 in 2017 and later was renovated and re-traded for $39,250,000; and the most expensive house sold in the Hamptons in 2022, which sold with the neighboring house for $118,500,000. Mr. Kelley’s portfolio of projects is valued at over $400,000,000. Although he has historically worked as a custom home builder, he would like to shift from providing a service to now providing a finished product in this market.

Market Opportunity

Mountain Top Capital Fund I has a target to raise $75 million to acquire, renovate and remarket Hamptons waterfront or water view properties. The fund has secured debt capital commitments for 70% of the acquisition costs and 100% of the construction costs and will use $10 million to leverage strategic waterfront opportunities in and around the Hamptons.

Profits from each project will be distributed upon the sale of the project, which is anticipated every 15 to 18 months, with a target of a minimum return on investment of 20% to 30% per transaction.

The company anticipates the fund’s Hamptons projects will be followed up by several other funds targeting additional high-end markets.

Management Team

Beau Kelley is CEO, President, CFO and Director of Mountain Top Properties.

Mountain Top Properties Inc. (OTC: MTPP), closed Friday's trading session at $0.0548, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0064/$0.0695.

Recent News

Longeveron Inc. (NASDAQ: LGVN)

The QualityStocks Daily Newsletter would like to spotlight Longeveron Inc. (NASDAQ: LGVN) .

Extended Follow Up Data Show Continued, Transplant Free Survival of All Patients

Results Support Continued Investigation of Lomecel-B TM As Adjunct to Stage II Surgery in HLHS

Enrollment ongoing in Phase 2 ELPIS II trial

Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) ("Longeveron" or "Company"), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, announced today that extended long-term follow-up data from the Company's ELPIS I trial of Lomecel-B TM for patients with hypoplastic left heart syndrome (HLHS) is being presented as a poster at the annual Scientific Sessions of the American Heart Association (AHA), being held in Philadelphia, PA on November 11-13, 2023.

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. The Company’s research and therapies are aimed at improving the outcome of infants born with a life-threatening heart condition, as well as improving the healthspan for the aging population – the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging, with function and ability to perform activities of daily living.

Longeveron is involved in clinical trials in the following indications: Hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.

The Company’s philosophy revolves around the idea that regenerative medicine may hold the potential to improve certain rare medical conditions and contribute to healthy aging. While there has been a remarkable rise in life expectancy over the last century due to medical and public health advancements, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging.

Longeveron’s lead investigational product is Lomecel-B™, an allogeneic Medicinal Signaling Cell therapy product isolated from the bone marrow of young, healthy adult donors. As humans age, they experience a decrease in immune system function, a decline in blood vessel functioning, chronic inflammation, and other issues. Clinical data has suggested that Lomecel-B™ may address these conditions through multiple mechanisms of action (MOA) that simultaneously target key aging-related processes.

The Company is headquartered in Miami, Florida.


Lomecel-B™ is being evaluated in multiple clinical trials for aging-related chronic diseases and other life-threatening conditions under U.S. FDA-approved Investigational New Drug applications. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas.

The drug is made from special living cells called Medicinal Signaling Cells (MSCs) that are isolated from fresh bone marrow tissue that has been donated by adult donors aged 18 to 45. Once the MSCs have been isolated from the fresh bone marrow through a careful selection process, the cells are culture-expanded (allowed to replicate under controlled laboratory conditions) into the billions using specialized techniques and processes. After a specific number of expansion cycles, called “passages,” the cells are harvested, separated into specific doses (e.g., 50 million cells), and cryopreserved until future use.

These cells have been shown to have characteristics that allow them to be transplanted from a donor to host without triggering a harmful immune response in the recipient, and they can be administered on an outpatient basis in as little as 40 minutes after thawing. Because of these characteristics, Lomecel-B™ is considered an “off-the-shelf” product.

In some trials, such as for Alzheimer’s disease and Aging-related Frailty, Lomecel-B™ is administered via peripheral intravenous infusion, while, in the Company’s HLHS trial, Lomecel-B™ is administered via direct injection into the heart tissue.

Market Opportunity

Longeveron estimates the potential market size for Lomecel-B™ in the treatment of HLHS to be up to $1 billion annually, globally.

U.S. patients suffering from Aging-related Frailty are estimated using U.S. Census Bureau statistics to be approximately 8.1 million. That population potentially represents a market for Lomecel-B™ of between $4 billion and $8 billion globally per year, according to Company estimates.

Additionally, the Alzheimer’s Association puts the number of Americans with that disease at 5.1 million, highlighting another potentially addressable market for Lomecel-B™, that’s worth $5 billion to $10 billion annually.

Management Team

Wa’el Hashad is CEO of Longeveron. He has more than 35 years of experience in the pharmaceutical and biotech industries. He has launched several successful brands in the U.S. and worldwide markets. Prior to joining Longeveron, he was president and CEO of Avanir Pharmaceuticals. Before Avanir, he was the chief commercial officer of Seres Therapeutics. He also has held senior leadership positions at Amgen, Boehringer Ingelheim, and Eli Lilly and Company. He holds a bachelor’s degree in pharmacy from Cairo University and an MBA from the University of Akron.

Joshua M. Hare, M.D., FACC, FAHA, is Co-Founder, Chief Science Officer and Chairman of Longeveron. He is a double board-certified cardiologist and is the founding director of the Interdisciplinary Stem Cell Institute at the University of Miami’s Miller School of Medicine. He is a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award and is an elected member of the American Association of Physicians and The American Society for Clinical Investigation. He is also an elected Fellow of the American Heart Association. He received a bachelor’s degree from the University of Pennsylvania and his M.D. from The Johns Hopkins University School of Medicine.

Lisa Locklear is CFO at Longeveron. She previously served as the senior vice president and CFO for Avanir Pharmaceuticals. Prior to Avanir, she held senior financial roles at GSN Games, CoreLogic, Ingram Micro, the Walt Disney Company, and Price Waterhouse, with assignments in Paris and London. She holds a bachelor’s degree in plant science from the University of California, Davis, and an MBA from the University of California, Irvine. She is a licensed CPA (inactive) and is a member of the American Institute of Certified Public Accountants, the California Society of CPAs, and Financial Executives International.

Dr. Nataliya Agafonova, M.D., is the Chief Medical Officer at Longeveron. She previously served as clinical development lead, senior medical director, and product development chair at Otsuka Pharmaceuticals. Before that, she was the clinical development lead and senior medical director at Bristol-Myers Squibb. She previously held senior leadership positions at Ardea Bioscience, Biogen, Amgen, and Genzyme Corporation. She earned an M.D. from the Ukrainian National Medical University and completed her internal medicine residency at Kharkov State University Hospital in Ukraine.

Certain statements in this corporate profile that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the Company’s product candidates, and other positive results; the timing and focus of the Company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the Company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company’s product candidates; the Company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the Company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the Company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company’s ability to attract and retain such personnel; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the second quarter of 2023 filed with the SEC on August 11, 2023. The forward-looking statements contained in this corporate profile are made as of the date of this corporate profile, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306

Date prepared: August 31, 2023

Longeveron Inc. (NASDAQ: LGVN), closed Friday's trading session at $1.82, off by 5.6995%, on 59,295 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.50/$4.5793.

Recent News

SenesTech Inc. (NASDAQ: SNES)

The QualityStocks Daily Newsletter would like to spotlight SenesTech Inc. (NASDAQ: SNES).

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, is reporting its third-quarter 2023 financial results and key achievements. According to the report, revenue growth increased 44% for the company compared to Q3 2022, with net loss improving by an estimated $700,00 for the same period while adjusted EBITDA loss, which is a non-GAAP measure of operating performance, was $1.7 million compared to $2.4 million in third quarter 2022. The company reported cash on hand at the end of the quarter to be $2.1 million. The report also noted that the company begins shipping its Evolve Soft Bait next week; the new product is projected to be a key driver for future revenue growth for SenesTech. "We accelerated our growth trajectory during the third quarter with strong 44% year-over-year growth in revenues driven by the initiatives we have undertaken to drive sales, improve our product quality, and expand our product options," said SenesTech president and CEO Joel Fruendt in the press release. "We expect this growth to further accelerate as we launch our Evolve Soft Bait, the first and only soft bait developed to control pest populations using a breakthrough technology that targets the rat population where it starts, by restricting fertility through nonlethal methods. We have received preorders and expect to start shipping product next week."

To view the full press release, visit

SenesTech Inc. (NASDAQ: SNES) is the rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats. The company’s technology provides an innovative and humane method for managing rat populations.

SenesTech is focused on developing effective solutions that are grounded in science and proven through research, all while providing value to people, communities and the environment. The company’s passion is to create a healthier world by better controlling rat pest populations. This aim is critical, as, if left unchecked, a breeding pair of rats and their descendants can produce up to 15,000 pups after just one year.

The company strives for clean cities, efficient businesses and happy households – with a product that was scientifically designed to be effective without killing rats. SenesTech is committed to the sustainable, humane treatment of animals, improving the quality of all human life and enhancing environmental stewardship through the global application of its effective solution in fertility control technology.

SenesTech is headquartered in Phoenix, Arizona.


SenesTech’s first product, ContraPest®, applies revolutionary technology to a global challenge that has persisted since the Middle Ages – the proliferation of rats in urban and agricultural settings. ContraPest® targets the reproductive capabilities of Norway and roof rats. As a highly palatable liquid, the formulation promotes sustained consumption, helping to reduce fertility in both male and female rats, bringing populations down and keeping them down.

The company’s flagship offering can be used as part of integrated pest management (IPM) programs – fitting seamlessly into all IPM programs – to help reduce reproduction and magnify the success of these protocols, or as a standalone solution for customers who want to reduce or eliminate the use of lethal rodent control methods.

In multiple, independent field deployments, ContraPest was shown to reduce rat activity over 90% when added to an existing IPM program.

ContraPest® is registered federally as a General Use Product.

Delivery Systems and New Products

In July 2023, SenesTech began to distribute a new delivery system for ContraPest®, the Isolate Bait System™. This new delivery system brings to market a simple design that enables more efficient deployment, incorporates an enhanced formulation of ContraPest® that is expected to provide improved performance of the fertility control bait in the field and is paired with a new bait station that is more space-efficient and economical.

The other delivery systems available for ContraPest include the Ultimate Bait System™, a tank and tray in a larger format for use with more severe infestations, and the Elevate Bait System™, a unique delivery system that targets above ground infestations, as with roof rats.

SenesTech, as of August 2023, is also in the final stages of releasing a soft bait formulation, which provides the unique attributes of proven fertility control in an industry-familiar format demanded by big box retailers, key e-commerce channels and leading industry pest management professionals.

Market Opportunity

According to SenesTech’s figures, rats cause over $27 billion in damage to public and private infrastructure annually in the United States. Rats also destroy 20% of the global stored food supply every year by consuming or contaminating it.

Rats are known to spread at least 35 diseases, globally posing a dangerous risk to public health and safety. Not only does this age-old problem persist despite extensive campaigns to eradicate it, but multiple sources have reported that post-COVID rat populations have boomed.

Poison-based control methods sicken rats, and they typically die slowly. An animal that eats a poisoned rat may also sicken or die. The global rodenticide market is projected to be worth $1.7 billion by 2026.

In one case study, results reported by the customer showed a $5,000 investment in ContraPest® saved more than $500,000 annually in reduced labor, loss and damage.

Management Team

Joel Fruendt is SenesTech’s President and CEO. He has 15 years of executive leadership in the vector and pest control industries as Vice President and General Manager of Clarke Environmental Inc., a leading vector and pest control products and services company. He has extensive expertise in the development and manufacturing of EPA-registered chemical control products, and the commercialization and sale of those products. He received the ‘Smart Leaders’ award from Smart Business Magazine and holds a bachelor’s degree in business from Illinois Wesleyan University.

Tom Chesterman is CFO at SenesTech. He has over 20 years of experience as the CFO of public companies in the life science, tech and telecommunications industries. Most recently, he was the Vice President and Treasurer of GCI, a telecommunications company. Previous to that, he was the CFO of life science companies Bio-Rad Laboratories, Aradigm and Bionovo. He has a bachelor’s degree from Harvard University and an MBA from the University of California at Davis.

Dan Palasky is Chief Technical Officer at SenesTech. Previously he held the title of Vice President of Research & Development at PLZ Corp., a manufacturer of chemical consumer products, serving as the technical expert for its entire product portfolio. He started his career with Camie-Campbell, Inc., as a chemist in the R&D department. Mr. Palasky received his bachelor’s degree in chemical engineering from the Missouri University of Science & Technology and his MBA in Project Management from Aspen University.

SenesTech Inc. (NASDAQ: SNES), closed Friday's trading session at $0.2385, off by 31.268%, on 689,466 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2208/$7.718.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a Canadian-based, growth-stage company committed to providing commercially viable and sustainable, cradle-to-cradle, clean-energy solutions, will be participating in the Rebuild Ukraine Conference next week. The event is scheduled to be held in Warsaw, Poland, on Nov. 13–16, 2023. According to the announcement, through its participation, FuelPositive is paving the way for sustainable agricultural and energy solutions as part of the Canadian Delegation at the conference, which signifies an essential worldwide effort to support the people of Ukraine in rebuilding their nation. Based on its vision and commitment to global food security, FuelPositive is in an ideal position to assist Ukrainian farmers in rebuilding their agricultural infrastructure through its ground-breaking technology that decarbonizes and decentralizes ammonia production and produces green ammonia (NH3) onsite, eliminating the need for traditional, centralized, carbon-intensive sources of ammonia.

"November 11 is Remembrance Day in Canada, and the FuelPositive team would like to acknowledge everyone around the world affected by the devastation of war and offer solidarity toward peace and rebuilding efforts," said FuelPositive board chair and CEO Ian Clifford in the press release. "FuelPositive would also like to extend its gratitude to the government of Canada for including us in its ongoing support and investment in clean technology research, development and adoption. Our company is committed to supporting sustainable and independent agricultural practices worldwide. We look forward to collaborating with stakeholders and exploring partnerships in a peaceful Ukraine, driving positive change and helping Ukrainian farmers reassert their full potential as agricultural leaders."

To view the full press release, visit

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Friday's trading session at $0.0545, off by 9.6186%, on 985,417 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.035/$0.1348.

Recent News


The QualityStocks Daily Newsletter would like to spotlight GEMXX Corp. (OTC: GEMZ) .

Gold prices defied significant resistance from a strong dollar and surging Treasury yields to reach the highest levels in nearly half a century in October. The precious metal saw its prices rise by 7.3% in October and closed the month at $1,983 an ounce, achieving the highest rally since 1978 when gold prices increased by a whopping 11.7%. Since gold doesn't earn any interest, its prices have traditionally faltered when bond yields went up, with higher bond yields causing gold prices to drop. With inflationary pressures forcing the U.S. Federal Reserve and other central banks to increase interest rates, gold prices plummeted as investors turned their attention to interest-bearing assets that would allow them to take advantage of the soaring interest rates. However, factors such as rapidly increasing geopolitical instability, fears of a recession, two ongoing wars, surging levels of national debt and credit-card delinquencies are quickly increasing gold's safe-haven appeal. The precious metal has historically acted as a safe haven asset, allowing individuals to store and preserve the value of their wealth during times of societal upheaval. The rising price of gold is likely to make jewelry makers such as GEMXX Corp. (OTC: GEMZ) ramp up their marketing strategies to top-tier customers who aren't likely to be fazed by the uptick in the price of the raw gold that is used to make prized jewelry.

GEMXX Corp. (OTC: GEMZ) is a mine-to-market enterprise specializing in gold, gemstone, and jewelry production. With ownership of mining resources, production facilities, and operational assets, the company maintains control over every aspect of its production process, from gold mining and gemstone extraction to jewelry manufacturing and global distribution.

As a prominent player in the industry, GEMXX stands out as a leading producer of high-quality finished Ammolite jewelry. Notably, it holds the distinction of being the sole public company engaged in Ammolite mining worldwide. In addition to its Ammolite operations, the company is actively involved in gold mining and prides itself on its ability to design and manufacture exquisite jewelry pieces and exceptionally rare, natural fossil decor items for clientele around the globe.

One of GEMXX’s key advantages lies in mining its own gold reserves to be utilized in its jewelry production. This strategic approach provides the company with a cost-saving edge over other producers in the market.

Ammolite is similar to black opal and is a biogenic gem like amber and pearl. It is derived from the fossilized shells of ammonites, a group of extinct marine nautiluses.

GEMXX’s world class gemstone cutters and jewelry designers are continuously leading the Ammolite industry. Its team believes in the company’s philosophy, vision and goals, and works every day to continue to drive the Ammolite industry to the forefront of the gem world.

The company has offices in Las Vegas and Hong Kong.

Projects and Operations

GEMXX has formulated an ambitious growth plan that, while challenging, is deemed attainable. The company’s strategy revolves around bolstering its market share through several key initiatives. Firstly, GEMXX aims to strengthen its position in current markets by nurturing and expanding existing relationships with customers and partners.

Secondly, the company plans to venture into untapped markets strategically. By identifying and targeting new areas, GEMXX seeks to establish a presence in regions that present promising opportunities for growth.

Additionally, GEMXX envisions growth through acquisitions. By considering and integrating key services, distribution networks and retail outlets into its fold, the company aims to consolidate its market position and capitalize on synergies for enhanced success.

To cater to the rising demand for its products, GEMXX has placed a primary focus on increasing gemstone production. The company’s southern properties, situated in Alberta, Canada, hold valuable deposits of rough Ammolite gemstone. By tapping into these resources, GEMXX is poised to meet the demand for its exquisite gemstone products and further fuel its expansion plans.


GEMXX possesses significant mineral assets in the form of a Mineral Work Permit covering an 800-acre area and two Ammonite Shell Mineral agreements encompassing 217 acres within the same region. The company’s management effectively operated mines in close proximity to these properties. Moreover, core sampling, along with fossil outcroppings on the riverbanks, confirms a substantial Ammolite resource present in these designated areas.

Both the Mineral Work Permit and the Ammonite Shell Mineral agreements grant GEMXX unrestricted access to all Ammolite resources within their respective demarcations. Notably, the company is not obligated to pay any royalties to third parties, thereby enabling GEMXX to fully capitalize on the potential of these valuable resources.

Furthermore, there are no stringent regulatory conditions that GEMXX must fulfill to gain or retain access to the Ammolite deposits. This freedom of access allows the company to proceed with its mining and production operations unimpeded, providing an advantageous position for future growth and success.

In March 2023, GEMXX made a significant announcement, revealing its acquisition of a 50% ownership stake in Crazy Horse Mining Inc., a Canadian gold mining company with assets situated in the province of British Columbia. As part of this deal, Crazy Horse’s assets, which encompass a 100% interest in two gold projects, called Snow Creek and Rosella Creek, spread across a substantial area exceeding 700 acres, now become part of GEMXX’s portfolio.

Under the terms of this strategic partnership, GEMXX and Crazy Horse will jointly share the expenses related to mining operations on these projects. Additionally, the two companies will share the gold produced from these ventures, leading to a collaborative and mutually beneficial arrangement.

Initial tests conducted on the property, combined with gold already recovered this season, confirm all expectations for the claims and substantiate the company’s estimated extraction target of over 100,000 ounces of easily recoverable gold. To validate and provide a more comprehensive assessment of this estimate, an S-K 1300-compliant Resource Report is scheduled to be conducted during the summer of 2023.

By acquiring this stake in Crazy Horse Mining Inc., GEMXX has positioned itself for further growth in the gold mining sector and is poised to capitalize on cost of goods savings in its jewelry business.

Market Opportunity

Leading independent market research companies such as Data Monitor and GIA estimate the worldwide market for luxury or premium lifestyle products, which include gems and jewelry, at over $90 billion annually and growing. Ammolite sales around the world have seen unprecedented growth over the past 20 years. Worldwide retail sales are now estimated to be over $100 million.

Ammolite jewelry and fossils are featured aboard cruise ships and can be found in specialty shops in almost every cruise port in North America. Asian markets have grown since feng shui master Edward Li called Ammolite the most influential stone of the new millennium, referring to it as the “Seven Color Prosperity Stone.” Home shopping channels in Japan, Australia, France, Germany, the UK, Canada and the U.S. have all featured Ammolite jewelry.

Ammolite and ammonites can also be found on many ecommerce sales platforms, including Amazon, eBay and Etsy. Ammolite is sold around the world in tourist and traditional jewelry markets. The company has established customers in home shopping channels, cruise tourism, jewelry retailers, Asian feng shui markets, Asian retail markets and ecommerce platforms.

Management Team

With over 160 years in Ammolite management, operations, and sales, GEMXX possesses an unparalleled wealth of knowledge and expertise. Its team members have extensive backgrounds in every facet of the Ammolite business, allowing the company to excel in product development, maintain rigorous quality control measures, and maximize profitability. The breadth and depth of the GEMXX team’s experience enable the company to navigate the industry with precision, ensuring that GEMXX remains at the forefront of the Ammolite market. GEMXX leverages its collective wisdom to drive innovation, deliver exceptional products, and optimize business strategies to achieve long-term success.

Jay Maull is Founder, CEO and Chairman of GEMXX. With a career spanning more than three decades, he has been deeply involved in the Ammolite industry, from mining and production to marketing. He has owned and operated the world’s largest Ammolite mine and has delivered exceptional Ammolite products to customers across all continents. He has also established the world’s largest Ammolite ecommerce platform.

Richard Clowater is President of GEMXX. He is a skilled sales and marketing professional with a focus on research, data analysis and strategic planning. He has successfully implemented initiatives to expand markets, boost profits and foster customer loyalty. He has an impressive track record of negotiating sales and contracts worth over $250 million with influential stakeholders, including key purchasing personnel, C-suite executives and government entities at all levels.

Tom Dryden is a Vice President of GEMXX and brings a wealth of experience and expertise to the production and marketing of Ammolite, spanning over 30 years. His extensive involvement in the industry has granted him unparalleled knowledge of the Bearpaw Ammonite bearing formations. As a recognized authority in the field, Mr. Dryden’s research and papers on Canadian Ammonites have garnered global recognition, being published worldwide. In his role at GEMXX, Mr. Dryden assumes the responsibility of overseeing the company’s Canadian-based production facilities. 

P. K. Chung is Business Manager Asia at GEMXX. With a track record of over 25 years in Ammolite business management, production and marketing in Asia, she is a recognized authority in the industry. Based in the Hong Kong gem district, she possesses an intricate understanding of the Asian gem and jewelry markets, including market dynamics, consumer preferences and industry trends specific to the region. Her strategic insights and deep connections enable GEMXX to thrive in this influential market.

GEMXX Corp. (OTC: GEMZ), closed Friday's trading session at $0.048, off by 10.2804%, on 640 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.023/$0.998.

Recent News

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)

The QualityStocks Daily Newsletter would like to spotlight Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF).

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) is a publicly traded exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec.

The company has an option to acquire a 99% interest in the highly prospective Iska Iska Property, classified as a silver-tin polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department of southern Bolivia. Iska Iska is a road-accessible, royalty-free property.

Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the North-Central Mineral Belt of Peru, some 50 kilometers south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine. La Victoria consists of eight mining concessions and eight mining claims encompassing approximately 89 square kilometers. La Victoria has good infrastructure, with access to road, water and electricity, and is located at an altitude that ranges from 3,150 meters to 4,400 meters above sea level.

The company has a strong management and technical team working diligently to uncover the value of both Iska Iska and La Victoria. Eloro is based in Toronto, Canada.


Iska Iska – Potosi, Bolivia

Iska Iska is associated with a Miocene possibly collapsed/resurgent caldera, emplaced on Ordovician age rocks with major breccia pipes, dacitic domes and hydrothermal breccias. The property is wholly controlled by the title holder, Empresa Minera Villegas S.R.L. It is located 48 kilometers north of Tupiza city, in the Sud Chichas Province of the Department of Potosi. This is an important mineral deposit type in the prolific South Mineral Belt of Bolivia. Eloro commissioned a NI 43-101 Technical Report on Iska Iska, which was completed by Micon International Limited and is available on Eloro’s website and under its filings on SEDAR.

A fully financed drill program is currently underway on the property, situated near world-class deposits including Silver Sand, San Bartolomé, Pulacayo, San Cristobal, San Vicente, Chorolque, Tasna, Choroma and Siete Suyos. Iska Iska is in the southwest part of the Eastern Cordillera, which hosts a number of major polymetallic mines and mineral deposits. Drilling and continuous channel sampling results have demonstrated some very high metal values, especially silver and tin, within an immense system, where mineralization has been encountered in every drill hole to date. The company believes there is excellent potential for world-class bulk mineable deposits.

La Victoria – Ancash, Peru

The La Victoria project, targeting gold and silver production, is situated near world-class, low-cost gold producers Pan American Silver and Barrick Gold Corporation. Located in Ancash Department, La Victoria sits on the western slopes of the Peruvian Andes. The property is located 12 hours from Lima, with a travel distance of 600 kilometers. The nearest road accessible population centers from La Victoria are Huandoval, Pallasca and Cabana. The project includes four principal mineralized zones in Peru’s prolific North-Central Mineral Belt – San Markito, Victoria, Victoria South and Ccori Orcco – with excellent potential for gold discovery. Operations at La Victoria are planned to proceed with a 2,000-meter diamond drilling program to test targets to outline potential resources at San Markito. Trenching and sampling confirmed high silver values and veins at San Markito in 2020.

Market Outlook

According to industry association The Silver Institute, the outlook for silver demand is exceptionally promising, with global demand forecast to rise to a record high of 1.112 billion ounces in 2022. The increase will be driven by record silver industrial fabrication, which is forecast to improve by 5%, as silver’s use expands primarily in solar energy and electric vehicle (EV) manufacturing. The institute states that government commitments to carbon neutrality have resulted in a rapid expansion of green energy projects, driving record photovoltaic panel installations which are expected to lift silver demand in this segment to an all-time high in 2022.

Rising demand in the electronics industry is also boosting the demand for tin, which is primarily used in solder. The electronics and electrical industries use solders containing 40-70% tin, which provide strong and reliable joints under a variety of environmental conditions. At present, the majority of the assemblers are using patented tin-and-copper-based solders. Mordor Intelligence estimated tin demand at 387 kilotons in 2021 and forecasts demand growth of 2.5% annually through 2027. Over the medium term, surging demand from the EV market and increasing applications in the electrical and electronics industry is expected to drive the market.

Management Team

Thomas G. Larsen is CEO of Eloro. He has more than 40 years of experience in the investment industry, specializing in corporate finance and management of junior resource companies, raising in excess of C$200 million. He previously held the position of President and Chief Executive Officer of Champion Iron Limited. Prior to that, he was President and Chief Executive Officer of Champion Iron Mines Limited.

Dr. Bill Pearson is Executive VP of Exploration for Eloro. He has more than 40 years of direct experience in the exploration and production of minerals worldwide. He played an integral role in the acquisitions of Desert Sun Mining Corp. by Yamana Gold in 2006 and Central Sun Mining by B2 Gold in 2009. He was formerly VP Exploration at Desert Sun Mining and Senior VP at Central Sun Mining.

Miles Nagamatsu, CPA, is CFO at Eloro. He has over 30 years of experience in accounting, management, lending, restructurings and turnarounds. Since 1993, he has acted as a CFO of public and private companies primarily in the mineral exploration and investment management sectors. He holds a Bachelor of Commerce degree from McMaster University.

Osvaldo Arce Burgoa is General Manager at Eloro. He is a geological and mineral processing engineer with 26 years of experience in Bolivia. He is a former President of the Bolivian Geological Society, Main Technical Advisor of the National Mining Corporation (COMIBOL) and has served as exploration manager and chief geologist at various mining and exploration companies. He has authored two books on Bolivian geology and holds a doctorate in mining engineering from Tohoku University in Sendai, Japan.

Eloro Resources Ltd. (OTCQX: ELRRF), closed Friday's trading session at $1.0815, off by 5.1316%, on 10,262 volume. The average volume for the last 3 months is 37,235 and the stock's 52-week low/high is $1.026/$3.135.

Recent News

Lucy Scientific Discovery Inc. (NASDAQ: LSDI)

The QualityStocks Daily Newsletter would like to spotlight Lucy Scientific Discovery Inc. (NASDAQ: LSDI).

Lucy Scientific Discovery Inc. (NASDAQ: LSDI) is an early-stage psychotropics manufacturing company focused on becoming the premier contract research, development and manufacturing organization for the emerging psychotropics-based medicines industry.

The company holds a Controlled Drugs and Substances Dealer’s License granted by Health Canada’s Office of Controlled Substances. This specialized license authorizes LSDI to develop, sell, deliver and manufacture pharmaceutical-grade active pharmaceutical ingredients (APIs) used in controlled substances and their raw material precursors. Lucy Scientific Discovery and its wholly owned subsidiary, LSDI Manufacturing Inc., operate under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada).

The company’s mission is to make its products and research services available for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs, including various mental health and addiction disorders. LSDI targets customers that include an increasing number of the leading universities, hospitals and other public, private and government institutions throughout the world that have launched research programs aimed at understanding the therapeutic potential of a range of psychedelic substances.

The company is headquartered in Victoria, British Columbia, Canada.


LSDI produces a variety of high-quality natural, synthetic and biosynthetic products to meet the needs of the rapidly growing psychotropics-based medicines market. The company believes the emerging psychotropics industry will pave the way to a brighter future in mental health and overall wellness. LSDI is dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies.

In Canada, the psychedelic compounds that LSDI is approved to produce under its Dealer’s License are regulated under the Controlled Drugs and Substances Act, or CDSA. Those compounds include:

  • Psilocybin
  • Psilocin
  • Lysergic acid diethylamide, or LSD
  • N,N-Dimethyltryptamine, or N,N-DMT
  • 3,4-Methylenedioxymethamphetamine, or MDMA
  • 4-Bromo-2,5-Dimethoxybenzeneethanamine, or 2C-B

The company also sells its consumer psychotropic products directly online and through retailers. Those products, described as microdose mushroom formulations, include a sleep aid, Twilight, and a mindfulness enhancer, Mindful.

Market Opportunity

According to a report from Global Market Insights, the psychotropics drug market had an estimated value of $20.2 billion in 2022 and is projected to reach a value of nearly $37.6 billion by 2032. That represents a CAGR of 6.4% for the forecast period. Factors driving market growth include the increasing prevalence of mental disorders, technological advancements in drug development, a rising geriatric population and increasing healthcare expenditures, the report states.

A growing awareness of mental health issues and an effort to reduce the stigma surrounding psychiatric disorders have encouraged more individuals to seek help, which in turn boosts the market. In addition, advancements in neuroscience, pharmacology and drug development have led to the discovery of new and more effective central nervous system therapeutics.

Innovative treatments offering better outcomes with fewer side effects attract patients and healthcare providers, also driving market growth.

Management Team

LSDI’s executive team brings deep experience in the development and commercialization of products featuring controlled substances, as well as the navigation of regulatory structures applicable to these products.

Richard Nanula is Chairman and CEO of LSDI. He has more than 35 years of leadership experience at several of the largest companies in the world, having been a senior executive at The Walt Disney Company, Amgen, Colony Capital and Starwood Hotels and Resorts. He has also served as a board member for Boeing Corporation and Starwood Capital, where he provided corporate guidance and oversight. He holds an MBA from Harvard Business School.

Assad J. Kazeminy, Ph.D., is Chief Scientific Officer at LSDI. He previously served as CEO of Irvine Pharmaceutical Services Inc. and Avrio Biopharmaceutical LLC, and he has founded several drug development companies. He has over 30 years of research and development experience in the biopharmaceutical industry. He received his Ph.D. in Pharmaceutical Science and Biochemistry from Esfahan University in Iran. He completed a Post Doctorate course of study at the University of Southern California Medical School, Department of Pharmacology.

Brian Zasitko, CPA, CA, is the company’s CFO. He is a Director of Invictus Accounting Group LLP, a professional services firm providing finance, advisory and accounting services. He also serves as CFO of Lobe Sciences Ltd., a company developing psychedelic compounds as therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. He has an undergraduate degree from Simon Fraser University and a CPA (CA) from Certified Professional Accountants, British Columbia.

Lucy Scientific Discovery Inc. (NASDAQ: LSDI), closed Friday's trading session at $0.2164, off by 15.1373%, on 466,015 volume. The average volume for the last 3 months is 232,285 and the stock's 52-week low/high is $0.20/$4.00.

Recent News

Horizon Fintex | Upstream

The QualityStocks Daily Newsletter would like to spotlight Horizon Fintex | Upstream

Horizon Fintex is a software business specializing in compliant securities solutions. The company aims to facilitate the future of capital markets by leveraging the regulatory experience of Wall Street bankers and the proven track record of technology veterans to bring focus to compliance, efficiency, security and transparency.

Horizon’s flagship product is the revolutionary trading app ‘Upstream’, a MERJ Exchange Market, and the first regulated market powered by a blockchain to offer both digital securities and NFT trading. Upstream traders experience T+0 settlement, best bids and offers displayed on a transparent public orderbook that prevents predatory market practices – all from a user-friendly trading app.


Horizon Fintex offers a full suite of end-to-end blockchain-enhanced software solutions to create a seamless experience for both issuers and investors. Its product suite includes:

  • Securitization & IssuanceETSware is an end-to-end Electronic Trading System streamlining capital raising from primary issuance through compliant secondary trading.
  • KYC Compliance OnboardingKYCware is a white label Know Your Customer (KYC) and Anti-Money Laundering (AML) compliance software solution offering best-in-class cryptographic security to compliantly onboard and verify user identity through a smartphone application.
  • AML Screening SoftwareAMLCop offers advanced Anti-Money Laundering (AML) software to streamline the verification of user details against a proprietary database of global sanctions, politically exposed persons (PEPs) and watchlists.
  • Cap. Table Management ToolsCustodyWare equips registered U.S. transfer agents with next-generation cap. table management software to manage securities on behalf of their clients pursuant to an SEC-registered or exempt securities offering.
  • Exchange & Trading App TechnologyOpen Order Book offers Ethereum blockchain securities exchange software to power the next generation of trading venues for digital assets.

Upstream – The Horizon-Powered Trading App

Upstream is a joint venture with MERJ Exchange (, an affiliate of the World Federation of Exchanges.

Upstream aims to be the premiere global trading hub offering issuers around the world exposure to a digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD (fiat) to increase liquidity and enhance price discovery; while also offering investors access to dual-listed companies, IPOs, crowdfunded companies, U.S. & Int’l. equities, digital coupons and NFTs directly from a user-friendly trading app.

Upstream aims to unlock liquidity for investors of all levels while offering industry-leading levels of transparency, accessibility and investor protections enforced using Ethereum blockchain technology.

Management Team

Brian Collins is the CEO of Horizon Fintex. He founded the company in 2010. From 1999-2010, Mr. Collins was CEO of Abbey Technology in Switzerland, specializing in the design of trading software for Swiss banks. Prior to this, he worked for Credit Suisse in Zürich, designing and building proprietary equity trading solutions. Mr. Collins graduated in 1990 with a BS in Computer Systems from the University of Limerick, Ireland.

Mark Elenowitz is the company’s President. He is a Wall Street veteran with over 29 years of experience. Mr. Elenowitz was the co-founder of a U.S. broker dealer and is Managing Director of two U.S. broker dealers, responsible for advising clients on compliance, capital structure and capital market navigation. He was responsible for leading the first successful Reg A+ IPO of a company to list on the NYSE and others which listed directly onto Nasdaq. He is a noted speaker at Small Cap and Reg A events, including the SEC Small Business Forum, and has been profiled in BusinessWeek and CNBC, as well as several other publications. Mr. Elenowitz is a graduate of the University of Maryland School of Business and Management with a BS in Finance and holds Series 24, 62, 63, 79, 82 and 99 licenses.

Dr. Andrew Le Gear is the CTO of Horizon Fintex. Prior to joining the company in 2013, he worked as a software engineer with Dell Inc. (2012-2013) and Lehman Brothers and Nomura Plc. (2007-2012). Dr. Le Gear was a co-founder of Juneberi Ltd., a research-driven software tech start-up (2004-2007). He graduated in 2006 with a Ph.D. in Computer Science from the University of Limerick, Ireland.

Peter Hall is the company’s CIO. Prior to joining Horizon Fintex in 2011, he worked at Microsoft (2008-2011), Atos Origin (2004-2008) and AIT Group Plc. (1998-2002). Mr. Hall has held CISSP certification since 2010. He graduated from the University of Sheffield, UK in 1995 and earned an MS from the University College London in 2006.

Mike Boswell is the CFO of Horizon Fintex. A Wall Street veteran, he co-founded a U.S. broker dealer and served as Chief Compliance Officer. Mr. Boswell was also Managing Director of TriPoint Capital Advisors, a merchant banking and financial consulting company, and CFO of Mission Solutions Group, a privately held defense sector firm. He earned an MBA from John Hopkins University and a BS in Mechanical Engineering from the University of Maryland. Mr. Boswell holds Series 24, 62, 63, 79, 82 and 99 licenses.

Recent News


The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.